Market capitalization | PLN17.96b |
Enterprise Value | PLN15.66b |
P/E (TTM) P/E ratio | 11.54 |
EV/FCF (TTM) EV/FCF | 17.03 |
EV/Sales (TTM) EV/Sales | 1.90 |
P/S ratio (TTM) P/S ratio | 2.18 |
P/B ratio (TTM) P/B ratio | 1.92 |
Dividend yield | 5.49% |
Last dividend (FY24) | PLN32.09 |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | 8,235 8,235 |
2%
2%
|
|
Gross Profit | 4,657 4,657 |
5%
5%
|
|
EBITDA | 2,169 2,169 |
17%
17%
|
EBIT (Operating Income) EBIT | 1,753 1,753 |
18%
18%
|
Net Profit | 1,559 1,559 |
13%
13%
|
In millions PLN.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
KRKA dd is a generic pharmaceutical company, which engages in the development, production, marketing, and sale of human and animal health products. It operates through the following geographical segments: European Union, South-East Europe, Eastern Europe, and Other. The European Union segment includes all countries of the European Union. The South-East Europe segment consists of Serbia, Bosnia and Herzegovina, Macedonia, Montenegro, Kosovo, and Albania. The Eastern Europe segment comprises of the Russian Federation and other former Soviet Union countries, excluding the Baltic countries. The company was founded by Boris Andrijanic in 1954 and is headquartered in Novo Mesto, Slovenia.
Head office | Slovenia |
CEO | Jože Colaric |
Employees | 11,780 |
Founded | 1954 |
Website | www.krka.biz |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.